A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

NCT06488313 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

OTC Deficiency
Ornithine Transcarbamylase Deficiency
OTCD

Interventions

BIOLOGICAL: ARCT-810

Sponsor

Arcturus Therapeutics, Inc.